Inhibition of erythropoietin-producing hepatoma receptor B4 (EphB4) signalling suppresses the vascularisation and growth of endometriotic lesions.

Jeannette Rudzitis-AuthSophia A FußVivien BeckerMichael D MengerMatthias W Laschke

Published in: British journal of pharmacology (2020)

Inhibition of EphB4 signalling suppresses the vascularisation and growth of endometriotic lesions. Hence, EphB4 represents a promising pharmacological target for the treatment of endometriosis.

Keyphrases

signaling pathway
combination therapy